What question did this study set out to answer?

This research aimed to develop a dissolvable microneedle vaccine to efficiently combat monkeypox using a replication-deficient orthopoxvirus platform.

March 21, 2026Open Access

View Full Paper

Dissolvable Microneedle Delivery of a Replication-Deficient Orthopoxvirus Vaccine: Formulation Screening and Immunogenicity Evaluation for Monkeypox Prevention

Key Points

This research aimed to develop a dissolvable microneedle vaccine to efficiently combat monkeypox using a replication-deficient orthopoxvirus platform.
Adopted a film-based approach for formulation screening and stability assessment.
Mixed NTV with excipients for solid film production and dried them.
Monitored stability using RT-qPCR at various temperatures.
Fabricated MVA-BN-loaded DMN patches for in vivo testing.
Evaluated immunogenicity through immunization of BALB/c mice.
Formulation F2 exhibited minimal potency loss of ~1 log10 after 2 months at 25 °C.
Less than 1 log10 loss was noted after 1 week at 37 °C.
SEM showed a porous morphology for virus entrapment.
FTIR analysis indicated improved bonding in the formulation.
DMNs successfully elicited robust MPXV-specific IgG and neutralizing antibodies, comparable to intramuscular injection.

Abstract

Background: The global spread of monkeypox virus (MPXV) highlights an urgent need for thermostable and easily administrable vaccines. Current orthopoxvirus vaccines are limited by cold-chain dependence and inconvenient injection-based delivery. Objectives: This study aimed to develop a dissolvable microneedle (DMN) vaccine against monkeypox based on a replication-deficient orthopoxvirus platform, through systematic formulation screening, stabilization mechanism exploration, and rigorous in vivo immunogenicity evaluation. Methods: A film-based approach was adopted for efficient, high-throughput formulation screening and thermostability assessment. NTV was mixed with excipients and dried into solid films. Stability was monitored via RT-qPCR after storage at 4 °C to 40 °C. The lead formulation was physically characterized, then used to fabricate MVA-BN-loaded DMN patches, which were further evaluated for in vivo immunogenicity via immunization in BALB/c mice. Results: The optimal formulation F2 (containing dextran, L-threonine, and BSA/HSA) showed a potency loss of only ~1 log10 after 2 months at 25 °C, and <1 log10 loss after 1 week at 37 °C. SEM revealed a porous virus-entrapment morphology, and FTIR indicated enhanced hydrogen bonding between the virus and the dextran matrix. The formulation was successfully manufactured into DMNs that dissolved within 5 min. In mice, these DMNs elicited robust MPXV-specific IgG and neutralizing antibody responses, with immunogenicity comparable to that induced by conventional intramuscular injection. Conclusions: This study successfully established a thermostable formulation and dissolvable microneedle delivery platform for replication-deficient orthopoxvirus vaccines against monkeypox. The optimized DMN vaccine induced robust MPXV-specific immune responses in mice with immunogenicity comparable to intramuscular injection, addressing the core limitations of current vaccines and providing a promising solution for monkeypox prevention.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Wang et al. (Fri,) studied this question.

synapsesocial.com/papers/69be3be16e48c4981c679c42 https://doi.org/https://doi.org/10.3390/vaccines14030276

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI से पूछें

Bookmark

View Full Paper